Phase II
The identification of multiple genomic markers that are linked to specific mental health diseases is beginning to improve treatments and enable precision psychiatry.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Pfizer has launched a Phase II/III study to assess its oral antiviral Paxlovid in non-hospitalized symptomatic pediatric patients who are at risk for progression to serious disease.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
BioNTech announced an expansion on its collaboration with Regeneron to continue advancing mRNA technology and develop novel treatments for a variety of cancers.
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
PRESS RELEASES